Intermediate results of the prospective randomized controlled trial VOG-01: "Evaluation of the efficacy of neoadjuvant combination hormone therapy in premenopausal patients with ER+ HER2- breast cancer". Voprosy onkologii, v. 68, n. 3, p. 354–361, 6 Jul.2022.